Intelligence Platform

Patents

Browse 2,465 pharma-relevant patents (US and EP, A61K/A61P) linked to tracked companies. Patent cliff and LOE intelligence for BD teams.

29,054 patents indexed

patent

US 11918565

Treatment of post-operative pain via sciatic nerve block with sustained-release liposomal

Pacira Pharmaceuticals, Inc. · Granted Tue Mar 05 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 29 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11918688

Treatment of hip pain with sustained-release liposomal anesthetic compositions

Pacira Pharmaceuticals, Inc. · Granted Tue Mar 05 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 29 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11913027

Methods of treatment using pluripotent human adipose adult stem cells

The Regents of the University of California · Granted Tue Feb 27 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 22 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11911385

Methotrexate treatment methods

Aldeyra Therapeutics, Inc. · Granted Tue Feb 27 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 22 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11911368

Method of treatment of CNS disorders

Supernus Pharmaceuticals, Inc. · Granted Tue Feb 27 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 22 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11903930

Methods and compositions for treatment of epileptic disorders

OVID THERAPEUTICS INC. · Granted Tue Feb 20 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 15 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11905268

Anthranilic acid derivatives and their use in the treatment of human cancers

SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE · Granted Tue Feb 20 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 15 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11897875

Deuterated Alpha5 subunit-selective negative allosteric modulators of gamma-aminobutyric a

The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Tue Feb 13 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 08 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11898158

Methods and compositions for the treatment of lysosomal storage diseases

Sangamo Therapeutics, Inc. · Granted Tue Feb 13 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 08 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11890415

Airway management systems for pulmonary disorder treatment

Covidien LP · Granted Tue Feb 06 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 01 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11890290

Topical treatment of wounds with statins and cholesterol for scar reduction

Northwestern University · Granted Tue Feb 06 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 01 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11891431

Removal of serine proteases by treatment with finely divided silicon dioxide

Takeda Pharm Limited ceutical Company Limited · Granted Tue Feb 06 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 01 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11890272

Non-sedating dexmedetomidine treatment regimens

BioXcel Therapeutics, Inc. · Granted Tue Feb 06 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 01 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11892450

Evaluation, assays and treatment of pKal-mediated disorders

Takeda Pharmaceutical Company Limited · Granted Tue Feb 06 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 01 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11884731

Vedolizumab for the treatment of fistulizing Crohn's disease

Takeda Pharmaceutical Company Limited · Granted Tue Jan 30 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 25 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11883492

Combination treatment of chemoresistant cancers

The Regents of the University of California · Granted Tue Jan 30 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 25 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11883381

ASH1L inhibitors and methods of treatment therewith

THE REGENTS OF THE UNIVERSITY OF MICHIGAN · Granted Tue Jan 30 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 25 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11879017

Anti-epidermal growth factor receptor variant III chimeric antigen receptors and use of sa

The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Tue Jan 23 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 18 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11878961

Next generation FKBP52 targeting drugs for the treatment of prostate and breast cancer

The Board of Regents of the University of Texas System · Granted Tue Jan 23 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 18 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11872200

GABA agonists in the treatment of disorders associated with metabolic syndrome and GABA co

The Regents of the University of California · Granted Tue Jan 16 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 11 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11872312

Neuroprotective liposome compositions and methods for treatment of stroke

The Board of Regents of the University of Texas System · Granted Tue Jan 16 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 11 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11873490

Antisense oligomers for treatment of conditions and diseases

STOKE THERAPEUTICS, INC. · Granted Tue Jan 16 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 11 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11866727

Materials and methods for treatment of glycogen storage disease type 1A

CRISPR THERAPEUTICS AG · Granted Tue Jan 09 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 04 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11866450

Modulators of Cystic Fibrosis Transmembrane Conductance regulator, pharmaceutical composit

Vertex Pharmaceuticals Incorporated · Granted Tue Jan 09 2024 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 04 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted